

**Request for information under the Freedom of Information Act – 2022.141  
Released – 12 September 2022**

Thank you for your email received 22 August 2022 requesting information regarding treatment within the Trust.

Please find detailed below a summary of your request, together with our response.

**Summary of your original request:**

***The purpose of these questions is to understand the variability of treatment within your trust and apply that to the context of the rest of the country.***

**Q1. How many patients has your trust treated (for any disease) in the last 6 months (or the latest 6 months data you have available) with the treatments listed below:**

- **Revolade (eltrombopag)**
- **Nplate (romiplostim)**
- **Doptelet (avatrombopag)**
- **Tavlesse (fostamatinib)**

None

**Q2. In the last 6 months (or the latest 6 months data you have available), how many patients has your trust treated for immune thrombocytopenia (ITP)?**

None

**Q3. Of the patients treated for immune thrombocytopenia (ITP) in the last 6 months (or the latest 6 months data you have available), how many were treated with:**

- **rituximab**
- **mycophenolate mofetil**
- **surgery (splenectomy)**

Not applicable

**Q4. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?**

No

Chair John Goulston Chief Executive Mairead McCormick

Trust HQ The Oast, Unit D, Hermitage Court, Hermitage Lane, Barming, near Maidstone, Kent ME16 9NT